PTO/SB/26 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

noter the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional) 2614 US0P

Reg. No. 43,032

In re Application of: M. Shiraishi Application No.: 10/018,321 Filed: December 12, 2001 For: Benzazepine derivatives, process for the preparation of the same and uses thereof 100 percent interest in the instant application hereby The owner*, Takeda Chem. Indus. Ltd., of _ disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. 2. The undersigned is an attorney or agent of record.

Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Elaine M. Ramesh, Ph.D., JD

Typed or printed name

(847) 383-3391 Telephone Number

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/26 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional) 2614 US0P

In re Application of: M. Shiraishi		
Application No.: 10/018,321		
Filed: December 12, 2001		
For: Benzazepine derivatives, process for the preparation of the same an	d uses thereof	
The owner*, <u>Takeda Chem. Indus. Ltd.</u> , of <u>100</u> disclaims, except as provided below, the terminal part of the state which would extend beyond the expiration date of the full statut shortened by any terminal disclaimer, of prior Patent No. <u>6,172,0</u> so granted on the instant application shall be enforceable only from commonly owned. This agreement runs with any patent granted its successors or assigns.	utory term of any patent granted on to ory term defined in 35 U.S.C. 154 061 B1	the instant application, and 173, as presently agrees that any patent nd the prior patent are
In making the above disclaimer, the owner does not disc application that would extend to the expiration date of the full s prior patent, as presently shortened by any terminal disclaime maintenance fee, is held unenforceable, is found invalid by a c whole or terminally disclaimed under 37 CFR 1.321, has all clair is in any manner terminated prior to the expiration of its full disclaimer.	tatutory term as defined in 35 U.S. er, in the event that it later: expire court of competent jurisdiction, is some canceled by a reexamination celes.	C. 154 and 173 of the es for failure to pay a tatutorily disclaimed in rtificate, is reissued, or
Check either box 1 or 2 below, if appropriate.		
1. For submissions on behalf of an organization (e.g., corp etc.), the undersigned is empowered to act on behalf of		ernment agency,
I hereby declare that all statements made herein of my information and belief are believed to be true; and further that the false statements and the like so made are punishable by fine or the United States Code and that such willful false statements m issued thereon.	ese statements were made with the imprisonment, or both, under Section	knowledge that willful on 1001 of Title 18 of
2. The undersigned is an attorney or agent of record.	we the second	
· · · · · · · · · · · · · · · · · · ·	Elaine M Kamesh	5/18/04
	Signature	Date
	Elaine M. Ramesh, Ph.D., JD	Reg. No. 43,032
	Typed or printed n	
	(847) 383-3391	
	Telephone Number	,
Terminal disclaimer fee under 37 CFR 1.20(d) included.	•	
WARNING: Information on this form may become put be included on this form. Provide credit card inform		
*Statement under 37 CFR 3.73(b) is required if terminal disclaims Form PTO/SB/96 may be used for making this certification. See		

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.